<![CDATA[Managing Gedatolisib IV Delivery and Toxicity Profiles in Breast Cancer]]>

<![CDATA[Gedatolisib Combination Approved for PIK3CA Wild-Type HR+, HER2– Breast Cancer]]>

Gedatolisib Combo Approved for Advanced Breast Cancer

Progression-free survival with the multitarget PAM inhibitor approaches 10 months after anti-CDK4/6 and aromatase inhibitor failure. Medscap

<![CDATA[Oncology PulsePoint: ASCO Updates Targeted Therapy for Stage IV NSCLC]]>

<![CDATA[From DREAMM-7 to DREAMM-8: Clinical Evidence, Conference Updates, and Managing Belantamab Mafodotin Adverse Events]]>

<![CDATA[Differentiating VMAT2 Inhibitors: Long-Term Management and Safety Data That Builds Confidence]]>

<![CDATA[Shifting the Paradigm: Evidence, Earlier Use, and Sequencing of BCMA-Targeted Therapies in Relapsed/Refractory Multiple Myeloma]]>